Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Dr. Gupta is currently a Hematology-Oncology fellow at Roswell Park Comprehensive Cancer Center in Buffalo, New York. The ASCO GI21 Merit Award recognizes oncology fellows and trainees who are first authors on top-ranking abstracts selected for presentation at the virtual Gastrointestinal Cancers Symposium, 2021. To read more about Dr. Gupta's study, visit https://meetinglibrary.asco.org/record/194118/abstract. For information on the ASCO GI21 Award, please see https://www.conquer.org/news/conquer-cancer-announces-2021-gastrointest….
Dr. Idalid “Ivy” Franco is a radiation oncology resident at the Harvard Radiation Oncology Program, in Boston, Massachusetts. She is the inaugural recipient of the Diversity Equity Inclusion Award with Dana-Farber/Brigham and Women's Cancer Center, awarded for her outstanding contributions towards efforts at diversity, equity and inclusion within the organization and related to the community at large.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: